# Advanced Breast Cancer Therapies
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/advanced-breast-cancer-therapies/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12829 |
| Works | 222 |
## Topic papers all
Showing 15 of 222.
- [Triple-Negative Breast Cancer](https://scholariq.org/papers/triple-negative-breast-cancer/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015](https://scholariq.org/papers/tailoring-therapies-improving-the-management-of-early-breast-cancer-st-gallen/)
- [A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-letrozole-in-postmenopausal-women-after-five-years-of/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [Breast cancer](https://scholariq.org/papers/breast-cancer/)
- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
## Topic primary papers
Showing 15 of 55.
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Breast cancer](https://scholariq.org/papers/breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial](https://scholariq.org/papers/elacestrant-oral-selective-estrogen-receptor-degrader-versus-standard-endocrine/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline](https://scholariq.org/papers/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer/)
- [Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer](https://scholariq.org/papers/advancements-in-clinical-aspects-of-targeted-therapy-and-immunotherapy-in-breast/)
- [Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study](https://scholariq.org/papers/adjuvant-abemaciclib-combined-with-endocrine-therapy-for-high-risk-early-breast/)
- [Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review](https://scholariq.org/papers/molecular-mechanisms-of-resistance-to-cdk4-6-inhibitors-in-breast-cancer-a/)
- [Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/switch-to-fulvestrant-and-palbociclib-versus-no-switch-in-advanced-breast-cancer/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.